PFE - Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market Despite Novo And Lilly's Dominance | Benzinga
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the burgeoning obesity market.
The pursuit involves developing innovative drugs or engaging in strategic acquisitions to compete with established players such as Novo Nordisk A/S (NYSE: NVO) and Eli Lilly And Co (NYSE: LLY).
At the JPMorgan health conference, Amgen unveiled plans for an experimental dual mechanism obesity drug currently in mid-stage trials.
In its presentation, Amgen Full story available on Benzinga.com